TGen News & Press Releases : TGen-led study confirms cell-free DNA in urine as potential method for cancer detection
Main Image

TGen-led study confirms cell-free DNA in urine as potential method for cancer detection

If successful, non-invasive method could transform detection and treatment outcomes

PHOENIX, Ariz. and DUARTE, Calif. — Feb. 17, 2021 — Urinalysis has long been a staple of physical exams to detect and manage a number of diseases and disorders, but not cancer. What if it were that easy, though, and cancer was detected in its very earliest stages when the disease responds more favorably to treatment and improved outcomes are more likely?

That was the question posed by scientists at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, who have found a way of zeroing in on early-stage cancer by analyzing short strands of cell-free DNA in urine. Their study’s findings were published today in the scientific journal Science Translational Medicine.

Previous thought once held that DNA fragments in urine were degraded at random and were too short to provide any meaningful information about a disease as complex as cancer. TGen and City of Hope researchers and their colleagues from Baylor University and Phoenix Children’s Hospital found that these DNA fragments are not random at all, and can clearly indicate a difference between healthy individuals and those with cancer. 

“There are many steps between where we are now and where we want to go — detecting cancer from a urine sample — but without doubt this is an encouraging first step,” said Muhammed Murtaza, M.B.B.S., Ph.D., an Associate Professor and Co-Director of TGen’s Center for Noninvasive Diagnostics, and the study’s senior author.

Dr. Murtaza previously led a team of TGen scientists who pioneered the use of circulating tumor DNA in blood, using genetic fragments to detect cancer with a simple blood draw. This “liquid biopsy” method sidesteps the need for many surgical biopsies of suspected tumors, and means that physicians can monitor cancer in their patients more frequently given the less invasive nature of the procedure.

Collecting a urine sample reduces the physical invasiveness to zero, Dr. Murtaza explained, and may eliminate a lab visit, given that the sample could be collected at home and mailed in for analysis.

By studying tissue samples from children with various cancers, whose malignancies often move extraordinarily fast, and adults with pancreatic cancer, whose early detection is critical to their disease outcomes, researchers mapped the DNA fragmentation profiles in their urine.

“We found that certain regions of the genome are protected from fragmentation in urine from healthy individuals, but the same regions are more fragmented in patients with cancer,” Dr. Murtaza said.

The fragmentation profiles were remarkably similar across multiple individuals; the length of the DNA fragments were similar, the regions of the genome where the fragmentation occurred were consistent, and informed researchers what type of cells contributed the fragments.

Ajay Goel, Ph.D., chair of the Department of Molecular Diagnostics and Experimental Therapeutics and Associate Director for Basic Science at City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, is one of the study’s authors. He is a leading expert in developing early-detection blood tests for colon, pancreatic and ovarian cancers.

“If the study results come to fruition, our urinalysis technology would be a remarkable breakthrough in the detection of many cancers, especially in pancreatic cancer,” Dr. Goel said. “If cancer is detected early, it could substantially lower the mortality rate for what is currently the third leading cause of cancer death in the U.S.”

While early results are promising, the researchers indicate the need to test their findings in much larger populations of cancer patients and identify differences between men and women, young and old, and those with co-morbidities, such as diabetes and other chronic diseases.

“This is a fundamental new finding and provides a potentially dynamic path forward for the early diagnosis of cancer, given that urine is one of the easiest samples to collect,” said Daniel D. Von Hoff, M.D., TGen Distinguished Professor and one of the paper's authors. "If follow-on studies yield positive results, I could one day see this test becoming an integral part of one's annual physical."

Support for this study — Analysis of recurrently protected genomic regions in cell-free DNA found in urine — was provided by the Ben and Catherine Ivy Foundation, the National Cancer Institute, Science Foundation Arizona, Arizona Women’s Board, and the Baylor Scott and White Research Institute.

NOTE: See a short video that helps explain the technology behind TGen’s urine cancer test at: https://youtu.be/69zwqn91BnM

# # #

About TGen, an affiliate of City of Hope
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based nonprofit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases: CityofHope.org.  This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children. Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: tgen.org. Follow TGen on FacebookLinkedIn and Twitter @TGen.

About City of Hope
City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hope’s translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution.  AccessHopeTM, a wholly owned subsidiary, was launched in 2019 and is dedicated to serving employers and their health care partners by providing access to City of Hope’s exceptional cancer expertise. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nation’s “Best Hospitals” in cancer by U.S. News & World Report. Its main campus is located near Los Angeles, with additional locations throughout Southern California and in Arizona. For more information about City of Hope, follow us on FacebookTwitterYouTube or Instagram.

TGen Media Contact:
Steve Yozwiak
TGen Senior Science Writer
602-343-8704
[email protected]

City of Hope Media:
Zen Vuong
City of Hope Media Relations
800-888-5323
[email protected] 


Media Contact



RSS Feed

Newsletter